Impact of COVID-19 on Translarna Managed Access Agreement – an update

Published Date
Emma Smith-Bodie

NICE, NHS England and NHS Improvement have reviewed the potential impact of COVID-19 on the delivery of the Managed Access Agreement (MAA) for Translarna, a treatment for people with Duchenne muscular dystrophy, after taking advice from clinical experts.

This is for patients and /or their carers who are already receiving treatment as well as those who have not yet started treatment.

The new advice takes into consideration the exceptional demand on the NHS now and in coming months as well as the fact that patients may want to continue self-isolation or have been told by their GP’s, clinician or hospital, to adhere to shielding.

As a result they have up-dated their information for patients.

MDUK has been asked to share their full statement which you can read here.

If you have questions about your individual circumstances and what is available to you at your usual treatment centre, don’t hesitate to contact the team who manage your treatment.

Keep in touch